Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab - A paradoxical effect? A case report;Agravamento de lesões refratárias de sarcoidose cutânea com adalimumab- um efeito paradoxal? Relato de um caso

Anais Brasileiros de Dermatologia

Volumn 88, Issue 6 SUPPL.1, 2013, Pages 26-28

  Santos, Guida ^a   Sousa, Lourdes Emerenciano ^b   João, Alexandre Miguel Bruno Lopes ^a  

^a HOSPITAL DE SANTO ANTÓNIO DOS CAPUCHOS   (Portugal)

^b Centro Hospitalar de Setubal   (Portugal)

Author keywords

Biological agents; Biological treatment; Sarcoidosis; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BISOPROLOL; HYDROXYCHLOROQUINE SULFATE; ISONIAZID; METHOTREXATE; METHYLPREDNISOLONE; PENTOXIFYLLINE;

ADULT; ARTICLE; BIOPSY; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE REDUCTION; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; MIDDLE AGED; SARCOIDOSIS; TUBERCULIN TEST;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; SARCOIDOSIS; SKIN DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890688702     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20132487     Document Type: Article

References (10)

1. Daldon PE, Arruda LH. Noninfectious granulomas: sarcoidosis. An Bras Dermatol. 2007:82:559-571.
2. Viguier M, Richette P, Bachelez H, Wendling D, Aubin F. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol. 2009;5:421-431.
3. Javot L, Tala S, Scala-Bertola J, Massy N, Trenque T, Baldin B, et al. Sarcoïdosis and anti-TNF: a paradoxical class effect? Analysis of the French Pharmacovigilance System database and literature review. Therapie. 2011;66:149-154.
4. Dhaille F, Viseux V, Caudron A, Dadban A, Tribout C, Boumier P, et al. Cutaneous sar-coidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology. 2010;220:234-237.
5. Callejas-Rubio JL, López-Pérez L, Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Ther Clin Risk Manag. 2008;4:1305-1313.
6. Thielen AM, Barde C, Saurat JH, Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology. 2009;219:59-62.
7. Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol. 2010;35:795-796.
8. Judson MA. Successful treatment of lupus pernio with adalimumab. Arch Dermatol. 2011;147:1332-1333.
9. Kaiser CA, Cozzio A, Hofbauer GF, Kamarashev J, French LE, Navarini AA. Disfiguring annular sarcoidosis improved by adalimumab. Case Rep Dermatol. 2011;3:103-106.
10. Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to ada-limumab. J Am Acad Dermatol. 2005;53:917.